Degenerative Myopia
📧 Sign up to get email alerts when something new happens for Degenerative Myopia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-21EMA Authorised: Rimmyrah (ranibizumab) — Qilu Pharma Spain S.L.
EU authorizes Rimmyrah (ranibizumab) from Qilu Pharma Spain S.L. for indications including wet age-related macular degeneration, macular ede…
-
EMA approval · 2026-06-15EMA Authorised: Rimmyrah (ranibizumab) — Qilu Pharma Spain S.L.
The EMA authorises Rimmyrah (ranibizumab) by Qilu Pharma Spain S.L. for multiple ophthalmic indications including wet age-related macular de…
-
EMA approval · 2026-02-26EMA Authorised: Yesafili (aflibercept) — Biosimilar Collaborations Ireland Limited
Yesafili is an authorised aflibercept biosimilar by Biosimilar Collaborations Ireland Limited for various retinal diseases, expanding treatm…
-
EMA approval · 2026-02-25EMA Authorised: Byooviz (ranibizumab) — Samsung Bioepis NL B.V.
EMA authorised Byooviz (ranibizumab) from Samsung Bioepis NL B.V. for multiple retinal diseases, including wet age-related macular degenerat…
-
EMA approval · 2020-09-16EMA Authorised: Visudyne (verteporfin) — CHEPLAPHARM Arzneimittel GmbH
EMA confirms authorisation of Visudyne (verteporfin) by CHEPLAPHARM Arzneimittel GmbH for indications related to degenerative myopia and mac…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.